Obesity attenuates gender differences in cardiovascular mortality [Elektronisk resurs]

• Background: To estimate cardiovascular disease (CVD) mortality in relation to obesity and gender. Methods: Data from 11 prospective cohorts from four European countries including 23 629 men and 21 965 women, aged 24 to 99 years, with a median follow-up of 7.9 years were analyzed. Hazards ratios (HR) for CVD mortality in relation to baseline body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) were estimated using Cox proportional hazards models with age as the timescale. Results: Men had higher CVD mortality than women in all four BMI categories (<25.0, 25.0-29.9, 30.0-34.9 and >= 35.0 kg/m(2)). Compared with the lowest BMI category in women, multivariable adjusted HRs (95% confidence intervals) for higher BMI categories are 1.0 (0.8-1.4), 1.6 (1.1-2.1) and 2.8 (2.0-3.8) in women and 2.8 (2.2-3.6), 3.1 (2.5-3.9), 3.8 (2.9-4.9) and 5.4 (3.8-7.7) in men, respectively. Similar findings were observed for abdominal obesity defined by WC, WHR or WHtR. The gender difference was slightly smaller in obese than in non-obese individuals; but the interaction was statistically significant only between gender and WC (p = 0.02), and WHtR (p = 0.01). None of the interaction terms was significant among non-diabetic individuals. Conclusions: Men had higher CVD mortality than women across categories of anthropometric measures of obesity. The gender difference was attenuated in obese individuals, which warrants further investigation. 

Ämnesord

Medical and Health Sciences  (hsv)

Clinical Medicine  (hsv)

Cardiac and Cardiovascular Systems  (hsv)

Medicin och hälsovetenskap  (hsv)

Klinisk medicin  (hsv)

Kardiologi  (hsv)

Endocrinology and Diabetes  (hsv)

Endokrinologi och diabetes  (hsv)

Indexterm och SAB-rubrik

Obesity

Gender

Cardiovascular disease mortality

SPRES JP

1990

ARTERIOSCLEROSIS

V10

P497 anworth Roger D.

2009

ADVANCES IN THE MANAGEMENT OF TESTOSTERONE DEFICIENCY

V37

P74 ngh R

2006

ENDOCRINOLOGY

V147

P141 at Altan

2014

CURRENT PHARMACEUTICAL DESIGN

V20

P575 gkos Faidon

2010

NUTRITION

V26

P686 maekers D

1998

EUROPEAN HEART JOURNAL

V19

P1334 Eon TM

2005

JOURNAL OF BIOLOGICAL CHEMISTRY

V280

P35983 meron A. J.

2013

OBESITY REVIEWS

V14

P86 rt AM

2002

CARDIOVASCULAR RESEARCH

V53

P678 effes MW

2004

ANNALS OF EPIDEMIOLOGY

V14

P492 emollieres FA

1999

ATHEROSCLEROSIS

V142

P415 ntague CT

1997

DIABETES

V46

P342 low B

2000

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

V85

P574 rshaw EE

2004

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM86th Annual Meeting of the docrine-Society

JUN 12-15

2004

New Orleans

LA

V89

P2548 G

2003

DIABETOLOGIA

V46

P608 rason K

1999

AMERICAN JOURNAL OF CARDIOLOGY

V83

P1242 ters HW

1999

JOURNAL OF INTERNAL MEDICINE

V246

P521